Tyrosine Kinase Inhibitors Market Report

Typically used as anticancer drugs, tyrosine kinase inhibitors, as the name suggests, inhibit tyrosine kinase enzymes that take the responsibility of the activation of several proteins by signal transduction cascades. A number of tyrosine kinase inhibitors have been proven to be effective as anti-leukemic and anti-tumor agents. Increasing investment in research and development activities is expected to set the tone for strong growth of the global tyrosine kinase inhibitors market. In May 2019, it was announced in a press release that the results of the phase 3 study of the Kit-PDGFRα kinase inhibitor ripretinib of Deciphera Pharmaceuticals, a US clinical-stage biopharmaceutical company, are ready to come out mid-2019.

The report offers useful guidelines for new as well as established companies to increase their sales and achieve a position of strength in the global tyrosine kinase inhibitors market.

Market Dynamics

Increasing application of tyrosine kinase inhibitors in the treatment of different types of cancer is expected to fuel the growth of the global market. The demand for tyrosine kinase inhibitors is predicted to improve with the growing prevalence of cancer around the globe. Moreover, tyrosine kinase inhibitors offer great advantages over radiotherapy and chemotherapy and have impressive efficacy and specificity. In addition, increasing awareness about cancer and its treatment in developing countries, unmet medical needs, and availability of pipeline tyrosine kinase inhibitors are anticipated to put a positive impact on the global market.

However, the expensive cost of tyrosine kinase inhibitors is prophesied to hamper the global market growth to some extent.

Market Segmentation

By Process

●   BCR-ABL TKIs

●   Vascular Endothelial Growth Factor (VEGFR) TKIs

●   Epidermal Growth Factor Receptor (EGFR) TKIs

●   Other TKIs

By Application

●   Chronic Myeloid Leukemia (CML)

●   Lung Cancer

●   Renal Cell Cancer

●   Breast Cancer

By Distribution Channel

●   Hospital Pharmacies

●   Online Pharmacies

●   Independent Pharmacies

According to analysts, VEGFR tyrosine kinase inhibitors are anticipated to become a prominent process segment due to their increased usage because of their multi-targeted kinase inhibitor activity. They are considered to be effective in the treatment of different types of soft tissue sarcomas. Among various applications of tyrosine kinase inhibitors, lung cancer is expected to show significant growth in the global market, considering its rising incidence across the world. Researchers predict independent pharmacies to show dominance in the global tyrosine kinase inhibitors market due to the expansion of international pharmacy service providers and the availability of their wide networks.

By Region

North America is prognosticated to collect a leading share of the global tyrosine kinase inhibitors market owing to high healthcare expenditure. Other factors such as high demand for targeted therapies and other advanced treatments are foreseen to further increase North America’s share of the global market. Analysts predict Asia Pacific to have a high attractiveness index because of the rising prevalence of lung cancer in China and India. Other Asia Pacific countries such as Australia and Japan show high adoption of digital healthcare technology and availability of well-established medical facilities.

Key Players

Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A are some of the prominent names of the global tyrosine kinase inhibitors market covered in the research study.

Research Methodology

The report answers important questions related to the growth of the global tyrosine kinase inhibitors market as well as its key segments. It offers detailed analysis of the current and future scenarios of the global market. It includes SWOT, Porter’s Five Forces, and qualitative and quantitative analyses to provide comprehensive and precise information and data related to the global market. It also provides thorough analysis of the regional growth and competitive scenario of the global market. Furthermore, the authors of the report have used reliable primary and secondary sources to estimate the overall market growth and give a detailed outlook for future years of the forecast period.

Reasons to Buy this Report

●     For exclusive data about the global Tyrosine Kinase Inhibitors market in our latest research report.

●     For authentic forecasts pertaining to capacity, production, value, consumption, growth rate (CAGR), market share, and milestones so far.

●     For a valuable insight into manufacturers, capacity, production, revenue, market share, and recent development.

●     For identifying significant trends, drivers, influence factors in global, and regions.

Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.

QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.